Abstract

Objective: To compare serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 between female patients with recurrent major depressive disorder (MDD) and healthy controls, verifying if there is a difference in the levels of these mediators between those with or without current suicidal ideation.

Methods: Thirty female outpatients with recurrent MDD were divided in two groups accordingly the presence or absence of suicidal ideation. These groups were compared with 16 healthy controls. Serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 were determined. Depression severity was evaluated by Beck Depression Inventory (BDI). Suicidal ideation was assessed by SCID-I and BDI.

Results: Patients with recurrent MDD and healthy controls did not differ in age, socioeconomic status, and education. All patients reported high scores of BDI (mean, SD, n; 29.75, 10.55, 28). Multivariable analysis of covariance adjusted for age and BMI showed that MDD patients with suicidal ideation presented lower levels of MCP-1/CCL2 and RANTES/CCL5 (p < 0.001) and higher levels of Eotaxin/CCL11 (p = 0.04) compared to healthy controls. These differences remained significant after adjusting for depression severity.

Conclusion: The findings of this study indicated that the presence of recurrent MDD with suicidal ideation is associated with differences in inflammatory chemokines when compared to those without suicidal ideation.

©2012 Elsevier Editora Ltda. All rights reserved.
Introduction

Suicide is a major problem in public health, with approximately 1 million people dying from suicide per year. Mental illnesses, particularly major depressive disorder, (MDD) are the main risk factor for suicide. Although several factors including personality and cultural and ethnic background may exert influence on suicidality of depressed patients, neurobiological factors involved in suicidal ideation and behavior has received considerable attention. Several studies have documented different biological changes in subgroups of individuals with MDD and suicidal behavior, including serotonergic and noradrenergic system abnormalities. Hypothalamus-pituitary-adrenal (HPA) axis dysfunction has also been reported.

A growing body of evidence has indicated the presence of a longstanding pro-inflammatory state in MDD. Increases in inflammatory mediators such as cytokines were extensively shown in MDD, with interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) being the most commonly associated with MDD. The causes for this pro-inflammatory state are largely unknown, although both genetic and environmental factors have been proposed as relevant. Chemokines, cytokines with chemotactic properties, have received less attention regarding their role in MDD. Nevertheless, these inflammatory mediators may be of particular interest in these patients, given their effect on the amplification of inflammatory response, possibly resulting in increased neuronal and glial death. For instance, peripheral chemokine levels seem to be altered in neurodegenerative disorders, such as multiple sclerosis and Alzheimer’s disease and in neuropsychiatric disorders such as schizophrenia.

and bipolar disorder. To date, more than 50 chemokines and approximately 20 chemokine receptors, particularly G-protein-coupled receptors, have been identified. The two largest families of chemokines, CCL and CXCL, attract mononuclear cells to sites of chronic inflammation. The binding of a chemokine to its receptor activates signaling cascades that lead to cell shape rearrangement and movement, namely chemokine (C-C motif) ligand 1 (Eotaxin/CCL11). Activation of these signaling pathways results in increased calcium concentrations and activation of mitogen-activated protein kinases, and also has a role in synaptic plasticity.

Studies exploring differences in inflammatory mediators across subgroups of depressive patients are scarce. A recent report indicated differences in cytokine concentrations among suicide attempters compared to non-suicidal depressed patients and healthy controls. Suicide attempters have increased levels of IL-6 and TNF-α as well as decreased levels of IL-2 concentrations. Unfortunately there are very few studies investigating the role of chemokines in major depression and suicide.

Because understanding the inflammatory mechanisms involved in MDD and suicide may potentially open new treatment possibilities, the aim of this study was to investigate chemokine differences between MDD individuals with and without suicidal ideation, in order to propose novel markers of suicidal ideation in MDD.
Peripheral chemokine levels in women with recurrent major depression with suicidal ideation

Methods

Thirty patients with recurrent MDD were recruited from a specialized outpatient clinic (Mood Disorders Program) at Hospital Presidente Vargas, Porto Alegre, Brazil. Psychiatric diagnosis was based on application of the Structured Clinical Interview for DSM-IV-Axis I Disorders (SCID-I). Depression severity was evaluated by Beck Depression Inventory (BDI). Suicidal ideation (SI) was assessed by SCID-I (“Over the last month: Have you wished you were dead?”; “Have you wanted to harm yourself?”; “Have you thought of committing suicide?”; and “Have you planned how to commit suicide?”) and BDI (“I have thoughts about committing suicide but I would not carry them out”; “I have definite plans about committing suicide”; “I would kill myself if I could”). Outpatients were classified according to whether they reported in both instruments to have (n = 18) or have not (n = 12) suicidal ideation. All patients had been using a stable dosage of antidepressant monotherapy at least for 3 months and were free of other medications for 4 weeks before blood collection. Exclusion criteria were: axis I comorbidities; severe or unstable clinical illness or illness associated with reports on abnormal immunological parameters; body mass index (BMI) above 30 kg/m²; neurological disorder; psychotic symptoms or any psychoactive substance used in past 30 days (except nicotine, caffeine, and antidepressants); current use of corticosteroids or nonsteroidal anti-inflammatory drugs; and acetylsalicylic acid or immunosuppressives.

Sixteen healthy volunteers were matched by age, social status, and BMI in MDD patients. Healthy control group was screened for psychiatric disorders using the non-patient version of SCID-I. Subjects included in the study were not using any medication, and their first-degree relatives had no history of major psychiatric disorders, dementia, mental retardation, cancer, or tumor. Exclusion criteria for healthy subjects were the same as those used in the selection of MDD patients. All participants had their socioeconomic status (SES) rated by the Hollingshead Index based on marital status, gender, occupation, and education.

Five milliliters of blood were collected from each subject by venipuncture in EDTA tubes. Samples were immediately centrifuged at 3000 g for 5 min, and plasma was kept frozen at -80°C until assayed. Plasma concentration of chemokines was determined using sandwich ELISA kits, following the manufacturer’s protocol (R&D Systems, Minneapolis, MN, USA). All samples were assayed in duplicate. Assay detection limit was 5 pg/mL.

Statistics

Descriptive analyses included assessment of the distribution of all variables; data are presented as means and percentages. Demographic and clinical characteristics were analyzed using the x²-test and analysis of variance (ANOVA), as indicated. Chemokine levels showed a non-parametric distribution and were analyzed after log transformation. Multivariable analysis of covariance (MANCOVA) was employed to compare mean differences between groups adjusting for those variables with significant differences in univariate ANOVAs. Statistical significance was set at p < 0.05. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS Inc., Chicago, IL, USA).

Results

Demographic and clinical characteristics of the sample (n = 49) are presented in Table 1. Both groups were homogeneous in terms of age, socioeconomic status, and education. All patients reported high scores of BDI (mean, SD; 29.75, 10.55, 28) presenting 11.5 years of illness duration (SD 5.58) and no medical comorbidities. As expected, outpatients with MDD and SI presented higher scores of depression severity. There were no differences between MDD with SI versus MDD without SI groups regarding the use of tricyclics (50% vs. 41.7%, p = 0.71), selective serotonin reuptake inhibitors (39% vs. 50%, p = 0.72), or other antidepressants use (11.1% vs. 8.3%, p = 0.99). The type of antidepressant had no influence on CCL2, CCL5, and CCL11 plasma levels (F = 2.52, p = 0.743) among MDD patients.

Multivariable analysis of covariance adjusted for age and BMI showed that MDD with SI presented lower levels of MCP-1/CCL2 and RANTES/CCL5 compared with MDD without SI and controls. Higher levels of Eotaxin/CCL11 in MDD with SI and MDD without SI were identified when compared to healthy controls. All differences remained significant after adjusting for depression severity (Figure 1). Assumptions for MANCOVA were tested and met. Independence was met through the study design; multivariate normality and linearity were assessed.

Table 1 Clinical and demographic characteristics of the sample and results of chemokine measurements

<table>
<thead>
<tr>
<th></th>
<th>Healthy Control (n = 16)</th>
<th>Non-suicidal Ideation (n = 12)</th>
<th>Suicidal Ideation (n = 18)</th>
<th>p</th>
<th>Post hoc test c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>38.12 (3.87)</td>
<td>37.75 (9.45)</td>
<td>40.17 (8.25)</td>
<td>0.643</td>
<td>HC = NSI = SI</td>
</tr>
<tr>
<td>Education (years)</td>
<td>8.56 (2.55)</td>
<td>8.58 (4.4)</td>
<td>7.83 (3.51)</td>
<td>0.783</td>
<td>HC = NSI = SI</td>
</tr>
<tr>
<td>BMI a</td>
<td>25.80 (1.73)</td>
<td>24.97 (2.42)</td>
<td>26.28 (2.10)</td>
<td>0.27</td>
<td>HC = NSI = SI</td>
</tr>
<tr>
<td>BDI b</td>
<td>5.12 (3.87)</td>
<td>20.83 (9.36)</td>
<td>33.61 (9.51)</td>
<td>&lt; 0.0001</td>
<td>HC = NSI &lt; SI</td>
</tr>
<tr>
<td>CCL2 (pg/mL)</td>
<td>536.74 (184.12)</td>
<td>523.94 (212.88)</td>
<td>535.97 (92.60)</td>
<td>0.004</td>
<td>HC, NSI &gt; SI b</td>
</tr>
<tr>
<td>CCL5 (pg/mL)</td>
<td>14,179.42 (452.92)</td>
<td>12,297.84 (1,703.47)</td>
<td>9,823.13 (2,786.36)</td>
<td>&lt; 0.0001</td>
<td>HC &gt; NSI &gt; SI b</td>
</tr>
<tr>
<td>CCL11 (pg/mL)</td>
<td>429.03 (272.85)</td>
<td>595.64 (183.11)</td>
<td>603.76 (281.21)</td>
<td>0.109</td>
<td>HC = NSI = SI</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD).

a Body Mass Index; b Beck Depression Inventory; c Gabriel’s procedure was used for post hoc comparisons; d Same results when controlling depression severity as a covariate (MANCOVA).
**Discussion**

The results of this study indicate the existence of differences in chemokine levels between recurrent MDD and healthy controls. In addition, the presence of SI affected significantly the chemokine profile. MDD with SI presented lower levels of MCP-1/CCL2 and RANTES/CCL5 in comparison with MDD without SI and healthy controls. In addition, the presence of SI affected significantly differences between MDD without SI and healthy controls in MCP-1 and RANTES levels. There were no statistically significant differences between MDD with and without SI in Eotaxin levels.

**Figure 1** Multivariable analysis of covariance adjusted for age and BMI.

Multivariable analysis of covariance adjusted for age and BMI showed that MDD with SI (n = 18) presented lower levels of MCP-1/CCL2 (M = 354.51 pg/mL, ± 39.75; F = 2.96, p = 0.031) and RANTES/CCL5 (M = 9,823.13 pg/mL, ± 2,786.36; F = 11.91, p = 0.001) in comparison with MDD without SI (n = 12) (MCP-1, M = 504.08 pg/mL, ± 50.89; RANTES, M = 12,384.56 pg/mL, ± 1,758.61) and controls (n = 16) (MCP-1, M = 537.24 pg/mL, ± 41.52; RANTES, M = 14,179.42 pg/mL, ± 452.92).

Higher levels of Eotaxin/CCL11 in MDD with SI (M = 603.76 pg/mL, ± 281.21) and MDD without SI (M = 591.92 pg/mL, ± 191.58) were identified when compared to healthy participants (M = 429.74 pg/mL, ± 272.85) (F = 2.77; p = 0.04). All differences remained significant after adjusting for depression severity. There were no statistically significant differences between MDD without SI and healthy controls in MCP-1 and RANTES levels. There were no statistically significant differences between MDD with and without SI in Eotaxin levels.

by examining bivariate scatter plots; and the Box’s Test of Equality of Covariance Matrices was used to test the null hypothesis, which showed that covariance matrices of dependent variables were equal across all groups (F = 1.40; p = 0.33).

**Disclosures**

Rodrigo Grassi-Oliveira  
*Employment: Developmental Cognitive Neuroscience Research Group, Post-Graduate Program in Psychology, Pontificia Universidade Católica (PUC-RS), Porto Alegre, Brazil.*

Elisa Brietzke  
*Employment: Program of Interventions in Individuals at Risk Mental States, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.*

Antônio Teixeira  
*Employment: Department of Internal Medicine, School of Medicine, Universidade Federal Minas Gerais (UFMG), Belo Horizonte, Brazil.*

Julio Carlos Pezzi  
*Employment: Post-Graduate Program in Health Sciences, Porto Alegre, Brazil.*
Peripheral chemokine levels in women with recurrent major depression with suicidal ideation

Márcio Zanini
Employment: Program of Interventions in Individuals at Risk Mental States, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.

Rodrigo Pestana Lopes
Employment: Institute of Biomedical Research and Faculty of Biosciences, Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil.

Moisés Evando Bauro
Employment: Institute of Biomedical Research and Faculty of Biosciences, Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil.

* Modest
** Significant
*** Significant: Amounts given to the author's institution or to a colleague for research in which the author has participation, not directly to the author.

References


2. Mann JJ, Currier DM. Stress, genetics and epigenetic effects in research in which the author has participation, not directly to the author.


8. Moisés Evandro Bauro